AMENDMENTDiscovery Collaboration Agreement • March 3rd, 2010 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT (the “Agreement”) is entered into effective December 9, 2009 (the “Effective Date”) by and between Ligand Pharmaceuticals Incorporated (“Ligand”) and Bristol-Myers Squibb Company (“BMS”).
DISCOVERY COLLABORATION AGREEMENT between PHARMACOPEIA, INC. and BRISTOL-MYERS SQUIBB COMPANYDiscovery Collaboration Agreement • March 6th, 2008 • Pharmacopeia Inc • Services-commercial physical & biological research • Delaware
THIS DISCOVERY COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of October 11, 2007 (the “Effective Date”), by and between Bristol-Myers Squibb Company, a Delaware Corporation (“BMS”) and Pharmacopeia, Inc., a Delaware Corporation (“Pharmacopeia”). BMS and Pharmacopeia each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
AMENDMENT OF DISCOVERY COLLABORATION AGREEMENTDiscovery Collaboration Agreement • February 7th, 2020 • Chanticleer Holdings, Inc. • Retail-eating places • California
This Amendment of the Discovery Collaboration Agreement (this “Amendment”) is made and entered into, effective as of May 7, 2019 (the “Effective Date”), by and between XOMA (US) LLC, a Delaware limited liability company having offices at 2200 Powell Street, Suite 310, Emeryville, California, 94608 (“XOMA”) and Sonnet BioTherapeutics, Inc., a New Jersey corporation, having offices ·at 1 Duncan Drive, Cranbury, NJ 08512 (“Sonnet”). Each of XOMA and Sonnet are sometimes referred to herein individually as a “Party” and together as the “Parties.”
